TrialThe oncologist2023

Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.

Van K Morris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.